{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:19:59Z","timestamp":1707524399237},"reference-count":13,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,11,8]]},"DOI":"10.7759\/cureus.19357","type":"journal-article","created":{"date-parts":[[2021,11,8]],"date-time":"2021-11-08T15:00:56Z","timestamp":1636383656000},"source":"Crossref","is-referenced-by-count":0,"title":["Dilated Cardiomyopathy in Pediatric Crohn\u2019s Patient: Is It a Manifestation or Consequence of Therapy?"],"prefix":"10.7759","author":[{"given":"Fadi","family":"Busaleh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hussain","family":"Albaqshi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salsabeel","family":"AlSultan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Alateeq","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Latifah A","family":"Alhashim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zakariya","family":"Aldandan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nawal","family":"Alfarhan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/s0889-8553(01)00002-4","article-title":"Epidemiology of inflammatory bowel disease","volume":"31","author":"Loftus EV Jr","year":"2002","unstructured":"Loftus EV Jr, Sandborn WJ. Epidemiology of inflammatory bowel disease. Gastroenterol Clin North Am. 2002, 31:1-20. 10.1016\/s0889-8553(01)00002-4","journal-title":"Gastroenterol Clin North Am"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.2147\/JIR.S65979","article-title":"Inflammatory bowel disease: clinical aspects and treatments","volume":"7","author":"Fakhoury M","year":"2014","unstructured":"Fakhoury M, Negrulj R, Mooranian A, Al-Salami H. Inflammatory bowel disease: clinical aspects and treatments. J Inflamm Res. 2014, 7:113-20. 10.2147\/JIR.S65979","journal-title":"J Inflamm Res"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2006.05.020","article-title":"Risks and benefits of infliximab for the treatment of Crohn's disease","volume":"4","author":"Siegel CA","year":"2006","unstructured":"Siegel CA, Hur C, Korzenik JR, Gazelle GS, Sands BE. Risks and benefits of infliximab for the treatment of Crohn's disease. Clin Gastroenterol Hepatol. 2006, 4:1017-24. 10.1016\/j.cgh.2006.05.020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S200147","article-title":"Infliximab and biosimilar infliximab in psoriasis: efficacy, loss of efficacy, and adverse events","volume":"13","author":"Subedi S","year":"2019","unstructured":"Subedi S, Gong Y, Chen Y, Shi Y. Infliximab and biosimilar infliximab in psoriasis: efficacy, loss of efficacy, and adverse events. Drug Des Devel Ther. 2019, 13:2491-2502. 10.2147\/DDDT.S200147","journal-title":"Drug Des Devel Ther"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.4103\/0378-6323.115526","article-title":"Tumor necrosis factor-\u03b1 antagonists: side effects and their management","volume":"79","author":"Dogra S","year":"2013","unstructured":"Dogra S, Khullar G. Tumor necrosis factor-\u03b1 antagonists: side effects and their management. Indian J Dermatol Venereol Leprol. 2013, 79:35-46. 10.4103\/0378-6323.115526","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1093\/eurjhf\/hfp132","article-title":"Severe cardiomyopathy following treatment with the tumour necrosis factor-a inhibitor adalimumab for Crohn\u2019s disease","volume":"11","author":"Emmert MY","year":"2009","unstructured":"Emmert MY, Salzberg SP, Emmert LS, et al.. Severe cardiomyopathy following treatment with the tumour necrosis factor-a inhibitor adalimumab for Crohn\u2019s disease. Eur J Heart Fail. 2009, 11:1106-9. 10.1093\/eurjhf\/hfp132","journal-title":"Eur J Heart Fail"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1161\/01.cir.0000017216.41471.df","article-title":"Sudden death in a patient without heart failure after a single infusion of 200 mg infliximab: does TNF-alpha have protective effects on the failing heart, or does infliximab have direct harmful cardiovascular effects?","volume":"105","author":"de\u2019 Clari F","year":"2002","unstructured":"de\u2019 Clari F, Salani I, Safwan E, Giannacco A. Sudden death in a patient without heart failure after a single infusion of 200 mg infliximab: does TNF-alpha have protective effects on the failing heart, or does infliximab have direct harmful cardiovascular effects?. Circulation. 2002, 105:183. 10.1161\/01.cir.0000017216.41471.df","journal-title":"Circulation"},{"key":"ref8","article-title":"Improvement of cardiomyopathy after infliximab treatment for Crohn's disease (CD)","volume":"102","author":"Mera RE","year":"2007","unstructured":"Mera RE, Banch H, Torres EA. Improvement of cardiomyopathy after infliximab treatment for Crohn's disease (CD). Am. J. Gastroenterol. 2007, 102:425-6.","journal-title":"Am. J. Gastroenterol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/s1388-984200121-6","article-title":"Clinical trials update: renewal (renaissance and recover) and attach","volume":"4","author":"Coletta AP","year":"2002","unstructured":"Coletta AP, Clark AL, Banarjee P, Cleland JG. Clinical trials update: renewal (renaissance and recover) and attach. Eur J Heart Fail. 2002, 4:559-61. 10.1016\/s1388-984200121-6","journal-title":"Eur J Heart Fail"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2019.08.060","article-title":"Iron deficiency is associated with adverse outcomes in pediatric heart failure","volume":"216","author":"Puri K","year":"2020","unstructured":"Puri K, Price JF, Spinner JA, et al.. Iron deficiency is associated with adverse outcomes in pediatric heart failure. J Pediatr. 2020, 216:58-66. 10.1016\/j.jpeds.2019.08.060","journal-title":"J Pediatr"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1097\/MPG.0000000000002311","article-title":"Anti-Saccharomyces cerevisiae antibodies as a prognostic biomarker in children with Crohn Disease","volume":"69","author":"Chandrakumar A","year":"2019","unstructured":"Chandrakumar A, Georgy M, Agarwal P, 't Jong GW, El-Matary W. Anti-Saccharomyces cerevisiae antibodies as a prognostic biomarker in children with Crohn Disease. J Pediatr Gastroenterol Nutr. 2019, 69:82-7. 10.1097\/MPG.0000000000002311","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.5009\/gnl.2012.6.4.512","article-title":"A case of acute myocarditis as the initial presentation of Crohn's disease","volume":"6","author":"Oh IS","year":"2012","unstructured":"Oh IS, Choi CH, Park JH, et al.. A case of acute myocarditis as the initial presentation of Crohn's disease. Gut Liver. 2012, 6:512-5. 10.5009\/gnl.2012.6.4.512","journal-title":"Gut Liver"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/3012509","article-title":"Cardiovascular manifestations of inflammatory bowel disease: pathogenesis, diagnosis, and preventive strategies","volume":"2019","author":"Bunu DM","year":"2019","unstructured":"Bunu DM, Timofte CE, Ciocoiu M, Floria M, Tarniceriu CC, Barboi OB, Tanase DM. Cardiovascular manifestations of inflammatory bowel disease: pathogenesis, diagnosis, and preventive strategies. Gastroenterol Res Pract. 2019, 2019:1-14. 10.1155\/2019\/3012509","journal-title":"Gastroenterol Res Pract"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/75766-dilated-cardiomyopathy-in-pediatric-crohns-patient-is-it-a-manifestation-or-consequence-of-therapy","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:33:18Z","timestamp":1707507198000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/75766-dilated-cardiomyopathy-in-pediatric-crohns-patient-is-it-a-manifestation-or-consequence-of-therapy"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,8]]},"references-count":13,"URL":"https:\/\/doi.org\/10.7759\/cureus.19357","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11,8]]}}}